Interferon-beta preparations (IFN-β) are immunogenic and development of neutralizing antibodies (NAb) to IFN-β is a significant cause of treatment failure in multiple sclerosis (MS) patients [1]. Here, IFNB1 is linked to multiple sclerosis.